Drug updated on 4/16/2024
| Dosage Form | Injection (intramuscular: 300 units, 500 units) |
| Drug Class | Acetylcholine release inhibitors and neuromuscular blocking agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of cervical dystonia in adults.
- For the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age.
- For the treatment of spasticity in patients 2 years of age and older.
Summary
- Abobotulinumtoxin A (Dysport) is indicated for the treatment of cervical dystonia in adults, temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults under 65 years old, and for the treatment of spasticity in patients aged 2 years and older.
- Three systematic reviews/meta-analyses were reviewed which provided information on Dysport's efficacy, safety profile, patient-reported outcomes, economic outcomes as well as its use for cosmetic purposes.
- One review compared abobotulinumtoxinA (aboBoNT-A) with onabotulinumtoxinA (onaBoNT-A) for treating refractory neurogenic detrusor overactivity; it found no significant differences between them regarding urinary incontinence episodes or urinary tract infections but suggested potential advantages of aboBoNT-A over onaBoNT-A concerning reduction of urinary incidents.
- Another study focused on using Dysport cosmetically to treat areas such as gummy/asymmetric smile, marionette lines, masseter muscle volume reduction etc., all articles reported positive results including wrinkle reduction and high patient satisfaction without any serious adverse events being reported.
- The third review assessed clinical evidence from placebo-controlled trials active-controlled trials and observational studies about Dysport's effects when used to treat Cervical Dystonia; it concluded that routine use was effective generally well-tolerated with a relatively low cost making it an established choice among health professionals dealing with CD cases.
- Despite some heterogeneity across studies observed during these analyses strong consistency trends suggest that this does not significantly impact conclusions drawn about abobotulinumtoxin A’s effectiveness or safety profile thus supporting its continued usage within specified indications mentioned above.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Dysport (abobotulinumtoxin A) Prescribing Information. | 2020 | Ipsen Biopharmaceuticals, Inc., Cambridge, Fort Worth. TX |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison. | 2023 | Journal of Medical Economics |
| Use of abobotulinumtoxina for cosmetic treatments in the neck, and middle and lower areas of the face: a systematic review. | 2021 | Toxins |
| Patient satisfaction with abobotulinumtoxina for aesthetic use in the upper face: a systematic literature review and post-hoc analysis of the APPEAL study. | 2021 | The Journal of Clinical and Aesthetic Dermatology |
| Onset and duration of abobotulinumtoxina for aesthetic use in the upper face: a systematic literature review. | 2020 | The Journal of Clinical and Aesthetic Dermatology |
| Use of abobotulinumtoxinA in adults with cervical dystonia: a systematic literature review. | 2020 | Toxins |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Oscar clinical guideline: botulinum toxin. | 2017 | OSCAR |